Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

Anne‐Laure Sellier‐Leclerc, Daniella Magen, Hadas Shasha‐Lavsky, Eva Šimková, Arnaud Devresse, Fitsum Guebre‐Egziabher, Mini Michael, John C. Lieske, Yaacov Frishberg, Sevcan A. Bakkaloğlu, Chebl Mourani, Rola Saqan, Richard Singer, Isabella Guzzo, Nune Makarova, Richard E. Willey, Cristin Kaspar, John M. Gansner, Jaap W. Groothoff